---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-085073"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2026-07-20T20:15:27+00:00"
generated_at: "2026-07-20T20:16:05.195207+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# TransCode shareholders approve preferred stock conversion, stock plan increase, and director elections

## Summary
- Approved conversion of Series A, B, and C preferred stock into common stock for Nasdaq listing compliance.
- Stockholders approved amendment to 2021 Stock Option Plan increasing available shares by 1,734,262.
- Elected six directors: Philippe P. Calais, Elizabeth Czerepak, Thomas A. Fitzgerald, Erik Manting, Magda Marquet, Jack E. Stover.
- Ratified WithumSmith+Brown, PC as independent auditor for FY 2026 with 393,497 votes for.
- Nasdaq approved the Company's initial listing application in connection with Proposals 1 and 2.

## SEC filing metadata
- accession: 0001104659-26-085073
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2026-07-20T20:15:27+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465926085073/0001104659-26-085073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465926085073/tm2620898d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-085073
- JSON: https://secwatch.observer/filing/0001104659-26-085073.json
- Plain text: https://secwatch.observer/filing/0001104659-26-085073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.